<article><a style="color: #000080;" href="http://www.dealstreetasia.com/?s=cvc">CVC Capital Partners</a> and Chinese drugmaker <a style="color: #000080;" href="http://www.dealstreetasia.com/?s=shanghai+pharma">Shanghai Pharmaceuticals Holding Co.</a> are in talks to team up on a bid for <a style="color: #000080;" href="http://www.dealstreetasia.com/?s=stada">Stada Arzneimittel AG</a>, people familiar with the matter said, as a bidding war for the German company heats up.</article>

<a style="color: #000080;" href="http://www.dealstreetasia.com/?s=cvc">CVC Capital Partners</a> and Chinese drugmaker <a style="color: #000080;" href="http://www.dealstreetasia.com/?s=shanghai+pharma">Shanghai Pharmaceuticals Holding Co.</a> are in talks to team up on a bid for <a style="color: #000080;" href="http://www.dealstreetasia.com/?s=stada">Stada Arzneimittel AG</a>, people familiar with the matter said, as a bidding war for the German company heats up.
The companies will make a decision about a joint bid as soon as next week, the people said, asking not to be identified as the deliberations are private. There’s no final decision yet on whether the firms will team up or make an offer, and CVC has also spoken to other Asian drugmakers, they said. Binding offers may be due this month, the people said.
Stada, whose shares have risen almost 80 percent in the past year, let a deadline for an offer from Advent for 3.61 billion euros ($3.81 billion) pass last month to keep the process open for other bidders. Private equity firms, sitting on record amounts of undeployed capital, are flocking to assets like Stada amid a shortage of deals.
CVC and Shanghai Pharmaceuticals would be competing against other consortia, including Advent International Corp., which may team up with Permira, and Bain Capital, which is in talks to join with Cinven Ltd., the people said. Singapore’s GIC Pte is also interested in making an offer as a co-investor with Advent, people familiar with the matter said previously.
Representatives for Stada, CVC, Advent, Permira, Cinven and Bain declined to comment. A spokeswoman for Shanghai Pharmaceuticals had no immediate comment outside of regular business hours.
Stada shares rose 0.6 percent to 56.86 euros at 3:35 p.m. in Frankfurt trading, giving the company a market value of about 3.5 billion euros.
A tie up with a drug company could help CVC extract greater cost savings from the purchase. CVC invested in another generic and biosimilar pharmaceutical firm called Alvogen in 2015. Advent’s other portfolio assets would give the private equity firm the greatest synergies out of the bidders, analysts at Bankhaus Lampe said in a note
Also read:
<a style="color: #ff0000;" href="http://www.dealstreetasia.com/stories/germanys-stada-has-received-a-third-higher-takeover-offer-65253/">Germany’s Stada has received a third, higher takeover offer</a>
<a style="color: #ff0000;" href="http://www.dealstreetasia.com/stories/drugmaker-stada-confirms-takeover-bid-from-two-companies-64788/">Drugmaker Stada confirms takeover bid from Cinven Partners</a>

China: CVC said to be in talks to join Shanghai Pharmaceuticals for Stada

China: CVC said to be in talks to join Shanghai Pharmaceuticals for Stada

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

China: CVC said to be in talks to join Shanghai Pharmaceuticals for Stada

Start your deal-making journey now!

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief